Clinical Trial Update: ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating INZ-701 for ENPP1 deficiency in infants, focusing on efficacy and safety; status ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Hypophosphatemic Rickets
• Ectonucleotide Pyrophosphatase Phosphodiesterase1 Deficiency
• Generalized Arterial Calcification of Infancy 1

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 3 | Status: ACTIVE_NOT_RECRUITING